Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Rustin GJ, et al. Among authors: piccart mj. J Clin Oncol. 2006 Jan 1;24(1):45-51. doi: 10.1200/JCO.2005.01.2757. J Clin Oncol. 2006. PMID: 16382112 Clinical Trial.
New cytostatic drugs in ovarian cancer.
Hansen HH, Eisenhauer EA, Hansen M, Neijt JP, Piccart MJ, Sessa C, Thigpen JT. Hansen HH, et al. Among authors: piccart mj. Ann Oncol. 1993;4 Suppl 4:63-70. doi: 10.1093/annonc/4.suppl_4.s63. Ann Oncol. 1993. PMID: 7906138 Review.
Advanced ovarian cancer. Dose intensity.
Ozols RF, Thigpen JT, Dauplat J, Colombo N, Piccart MJ, Bertelsen K, Levin L, Lund B. Ozols RF, et al. Among authors: piccart mj. Ann Oncol. 1993;4 Suppl 4:49-56. Ann Oncol. 1993. PMID: 8312201 Review.
Intergroup collaboration in ovarian cancer: a giant step forward.
Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye SB, Tropé C, Swenerton K, Harper P, Vermorken JB. Piccart MJ, et al. Ann Oncol. 1999;10 Suppl 1:83-6. doi: 10.1023/a:1008371821148. Ann Oncol. 1999. PMID: 10219459
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabbeke M, Lacombe D, Pinel MC, Pecorelli S. Piccart MJ, et al. J Clin Oncol. 2000 Mar;18(6):1193-202. doi: 10.1200/JCO.2000.18.6.1193. J Clin Oncol. 2000. PMID: 10715288 Clinical Trial.
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Piccart MJ, et al. J Natl Cancer Inst. 2000 May 3;92(9):699-708. doi: 10.1093/jnci/92.9.699. J Natl Cancer Inst. 2000. PMID: 10793106 Clinical Trial.
594 results